Drug Profile

Omadacycline - Paratek Pharmaceuticals

Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; NUZYRA; PTK-0796; ZL 2401

Latest Information Update: 28 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tufts University
Developer Merck & Co; Paratek Pharmaceuticals; ZAI Lab
Class Anti-infectives; Anti-inflammatories; Antibacterials; Small molecules; Tetracyclines; Urinary anti-infective agents
Mechanism of Action Protein synthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Nontuberculous mycobacterium infections
New Molecular Entity Yes

Marketed Community-acquired pneumonia; Skin and soft tissue infections
Preregistration Anthrax
Phase II Cystitis; Nontuberculous mycobacterium infections; Pyelonephritis; Urinary tract infections
No development reported Acute sinusitis; Bacterial infections; Plague
Discontinued Nosocomial infections

28 Jun 2025 No recent reports of development identified for phase-I development in Bacterial-infections(In adolescents, In children) in USA (IV)
08 Nov 2024 Efficacy, adverse events and antimicrobial data from a phase II clinical trials in Nontuberculous mycobacterium infections was released by Paratek Pharmaceuticals
17 Jul 2024 Paratek Pharmaceuticals completes a phase II trial in Nontuberculous mycobacterium infections in USA (PO) (NCT04922554)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com